The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Annual Report

  December 17, 2019

Company Presentation

CEO Comments

Read More
  Quarterly Report 3 19/20, June 24, 2020

Dear Shareholders and readers

We are currently looking forward to the topline results from our ongoing Phase IIb trial DIAGNODE-2. In this innovative trial, the diabetes vaccine Diamyd® is administered into a superficial lymph node. This novel administration route enhances the immunological effect of the vaccine by directly targeting the immunological site of action, and results from the pilot trial DIAGNODE-1 support superior clinical efficacy compared to the subcutaneous route used in previous trials....

The topline results from DIAGNODE-2 will comprise both the primary clinical endpoint and the most important secondary clinical endpoints, as well as the results for the genetically defined subgroups. These results will have an impact on the final design of any upcoming late stage development trials, including the patient population that we will target for the drug label.
Ulf Hannelius, President and CEO

Calendar

  
September 1 − September 4, 2020
LSX Nordic Congress
October 7, 2020
Year-End Report
Year-End Report 2019/2020
November 5, 2020
Annual Report
Annual Report 2019/2020
November 26, 2020
Annual General Meeting
Annual General Meeting 2019/2020
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of June 30, 2020

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 9 206 538 13.31 9.99
Essen-Möller, Anders 2 556 223 6 333 040 12.85 34.60
Lindkvist, Bertil 6 500 000 9.40 7.05
Nordnet Pension 2 421 455 3.50 2.63
Hansen, Patrik 830 000 1.20 0.90
Swedbank Försäkring 798 822 1.15 0.87
Konstruktions o Försäljningsaktiebolag 750 745 1.09 0.81
Arandi Development AB 510 000 0.74 0.55
Schelé, Sven 485 000 0.70 0.53
Relbo AB 475 550 0.69 0.52
Remaining shareholders 38 302 423 55.37 41.55
Total 2 556 223 66 613 573 100.0 100.0

Order GAD for preclinical research

ORDER

Annual Report

  December 17, 2019
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden
+46 8 661 00 26
+46 8 661 63 68

Subscribe

   

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research